Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas

التفاصيل البيبلوغرافية
العنوان: Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas
المؤلفون: Whitson, RJ, Lee, A, Urman, NM, Mirza, A, Yao, CY, Brown, AS, Li, JR, Shankar, G, Fry, MA, Atwood, SX, Lee, EY, Hollmig, ST, Aasi, SZ, Sarin, KY, Scott, MP, Epstein, EH, Tang, JY, Oro, AE
المصدر: Whitson, RJ; Lee, A; Urman, NM; Mirza, A; Yao, CY; Brown, AS; et al.(2018). Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nature Medicine, 24(3), 271-281. doi: 10.1038/nm.4476. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/8hs9c3sv
بيانات النشر: eScholarship, University of California, 2018.
سنة النشر: 2018
الوصف: © 2018 Nature America, Inc., part of Springer Nature. All rights reserved. Hedgehog pathway-dependent cancers can escape Smoothened (SMO) inhibition through mutations in genes encoding canonical hedgehog pathway components; however, around 50% of drug-resistant basal cell carcinomas (BCCs) lack additional variants of these genes. Here we use multidimensional genomics analysis of human and mouse drug-resistant BCCs to identify a noncanonical hedgehog activation pathway driven by the transcription factor serum response factor (SRF). Active SRF along with its coactivator megakaryoblastic leukemia 1 (MKL1) binds DNA near hedgehog target genes and forms a previously unknown protein complex with the hedgehog transcription factor glioma-associated oncogene family zinc finger-1 (GLI1), causing amplification of GLI1 transcriptional activity. We show that cytoskeletal activation through Rho and the formin family member Diaphanous (mDia) is required for SRF-MKL-driven GLI1 activation and for tumor cell viability. Remarkably, nuclear MKL1 staining served as a biomarker in tumors from mice and human subjects to predict tumor responsiveness to MKL inhibitors, highlighting the therapeutic potential of targeting this pathway. Thus, our study illuminates, for the first time, cytoskeletal-activation-driven transcription as a personalized therapeutic target for combatting drug-resistant malignancies.
وصف الملف: application/pdf
اللغة: English
URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______325::93553ba47d1b5fc46da3b0f02f345fa5
http://www.escholarship.org/uc/item/8hs9c3sv
حقوق: OPEN
رقم الأكسشن: edsair.od.......325..93553ba47d1b5fc46da3b0f02f345fa5
قاعدة البيانات: OpenAIRE